natgillin/translations-raw huggingface dataset:
A sixteenth example concerns a partial sugar replacement composition still containing an amount of sucrose. 
U šesnaestom primjeru opisuje se sastavina koja djelomice zamjenjuje šećer i koja još uvijek sadržava određenu količinu saharoze.
The compound of formula (VIII) is commercially available or may be obtained by applying or adapting any known methods or those described in the examples to obtain the desired compound of formula (VIII) from available starting products. 
Spoj formule (VIII) dostupan je na tržištu ili ga se može dobiti primjenom ili prilagođavanjem bilo kojeg poznatog postupka ili onih opisanih u primjerima kako bi se dobilo željeni spoj formule (VIII) iz dostupnih polaznih produkata,
Therefore it is an object of the present invention to identify these portions and to provide therefore the means to create AOX1 promoters with enhanced features. Therefore the present invention relates to a mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: 
PATENTNI ZAHTJEVI L Promotor alkoholne oksidaze | mutantne Pichia pastoris (AOX1), naznačen time, da je to promotor divljeg tipa Pichia pastoris AOX1 (SEQ ID No.1) koji sadrži najmanje jednu mutaciju unutar nukleotida 170 do 235 (-784 do - 719) od SEQ ID No.1 za visoku ekspresiju pod uvjetima induciranog metanola.
Method according to claim 11, in which the stay cable array is constituted of at least three stay cables, and in which dampers link at least certain pairs of adjacent stay cables of the stay cable array, at least one of said dampers having a first stiffness in response to tensile stress and a second stiffness in response to compressive stress, the first stiffness being greater than the second stiffness. 
Postupak sukladno zahtjevu 11, pri čemu je niz kablova (4, 5) načinjen od barem tri kabela, i pri čemu amortizeri (6) povezuju barem određene parove susjednih kablova niza kablova, barem jedan od amortizera ima prvu čvrstoću kao odgovor na vlačnu napetost i drugu čvrstoću kao odgovor na tlačnu napetost, prva napetost je veća od druge napetosti.
a mass suitable to be subjected by the driving means to an alternate motion, namely a mass oscillating substantially along the direction of a vertical axis (Z) and comprising at least one restricted environment where substances in a solid and/or liquid state receive a physical or chemical-physical treatment by the kynetic energy of milling bodies (14; 89); 
- masa koju se može podvrgnuti pogonu kako bi se postiglo promjenjivo gibanje, naime masa koja oscilira uglavnom u smjeru okomite osi (Z) i sadrži najmanje jedan ograničeni okoliš gdje se na tvarima u čvrstom ifili tekućem stanje vrši fizička ili fizičko-kemijska obrada kinetičkom energijom tijela za mljevenje (14; 89);
Other “therapeutic agent(s)” suitable for combination with the compound of the present invention include, but are not limited to, known therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents; anti-hyperglycemic agents; hypolipidemic/lipid lowering agents; anti-obesity agents; anti-hypertensive agents and appetite suppressants. 
Druga "terapeutska sredstva" pogodna za kombiniranje sa spojem prema ovom izumu su izabrana iz grupe koju čine poznata terapeutska sredstva korisna u liječenju prethodno navedenih poremećaja: anti-dijabetična sredstva; anti-hiperglikemijska sredstva; hipolipidemijska sredstva/sredstva za snižavanje nivoa lipida; sredstva protiv debljine; anti-hipertenzivna sredstva i sredstva koja smanjuju apetit.
As shown in Figure 15, the container may include a plurality of openings 1501 that are spaced about the top of the container cap 1500 . 
Kako je prikazano na Slici 15, posuda može uključiti vise otvora 1501 smještenih na gornjoj površini poklopca 1500 za posudu.
The compound of claim 31, wherein the -(C1-C6) alkyl group is a tert-butyl group or an iso-propyl group. 
Spoj prema zahtjevu 31, naznačen time da -(C;-C4) alkilna skupina je tert-butilna skupina ili izo-propilna skupina.
B is a divalent metal cation; 
B je dvovalentni metalni kation;
Additives are in common use for purposes of aiding in the preservation of the crop during storage. 
Aditivi se obično koriste u cilju pomaganja održavanja usjeva tijekom skladištenja.
Medical Treatment of the Patient with vaccine: 
Broj objave europskog patenta:
pyridinyl optionally substituted with: -NR9R10, -NHC(O)R9, 
piridinil opcijski supstituiran sa sljedećima:
The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 4, wherein Ar1 is substituted with a C1-6 alkyl group. 
Spoj ili njegova farmakološki prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da je Ar1 supstituiran s C1-6 alkilnom skupinom.
The anti-CD79b antibody of claim 14, wherein the multispecific or bispecific antibody comprises a CD3 binding domain. 
Anti-CD79b protutijelo patentnog zahtjeva 14, naznačeno time, da multispecifično ili bispecifično protutijelo sadrži domenu vezivanja CD3.
The pharmaceutical composition according to any one of the preceding claims, wherein said first type of granules further comprises (i) a lubricant, such as magnesium stearate, and/or (ii) a filler, such as microcrystalline cellulose. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni prvi tip granula dodatno sadrži (1) mazivo, poput magnezijevog stearata, i/ili (1i) punilo, poput mikrokristalne celuloze.
the serine at position 130, 136 and 139 and the threonine at position 133 and 135 are replaced with an alanine, 
serin na položaju 130, 136 i 139 i treonin na položaju 133 i 135 su zamijenjeni sa alaninom,
A process according to claim 1 wherein the emulsion or dispersion comprises an active principal or carrier substance. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 12, pri čemu emulzija ili disperzija obuhvaća aktivnu osnovu ili tvar nosač pogodnu za liječenje inhaliranjem.
to 0.5 mg of human granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant, preferably 0.25 or 0.125 mg of the GM-CSF. 
(1i) kao adjuvant 0.01 do 0.5 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF), a poželjno 0.25 ili 0.125 mg GM-CSF.
Het16 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C1-4alkyl; and Het17 represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-; 
Het16 predstavlja heterocikal odabran od morfolinil, pirolidinil, piperazinil, 1,3,2-dioksaborolan ili piperidinil pri čemu navedeni heterocikal je proizvoljno supstituiran sa jednim ili više supstituenata odabranih iz skupine koja sadrži C1-4alkil; i Het17 predstavlja heterocikal odabran od pirolidinila ili piperidinila proizvoljno supstituiran sa jednim ili gdje je moguće sa dva ili više supstituenata koji su odabrani iz skupine koja sadrži C1-4alkil, C3-6cikloalkil, hidroksi-C1-4alkil-, C1-4alkiloksiC1-4alkil ili polihidroksi-C1-4alkil-;
A sixth embodiment provides a process for the preparation of compounds of formula (3) or (IV) comprising: 
(Ža) ili njegove soli, sa sredstvom za sulfoniranje, da se dobije spoj formule (IV):
wherein the additive composition is boron-free by containing less than 0.5 wt% boron and free of a secondary amine by containing less than 0.5 wt% secondary amine. 
pri čemu je pripravak aditiva bez bora s udjelom od manje od 0.5 mas.% bora i bez sekundarnog amina s udjelom od manje od 0.5 mas.% sekundarnog amina.
A compound of the formula: 
Spoj sukladno zahtjevu 1, s formulom:
tabletting the granules of step (3) or the final mixture of step (4) by compressing it on a suitable tablet press to produce matrix tablets. 
(5) tabletiranje granula iz koraka (3) ili konačne mješavine iz koraka (4) njezinim komprimiranjem u prikladnoj preši za tablete da bi se pripravile matrice tableta.
In accordance with another preferred embodiment of the present invention, the method includes: mixing a stream of a hypochlorite solution with a stream of the ammonium salt dilution in a mixing chamber at a starting ratio; holding the flow rate of one of the streams constant and gradually increasing or decreasing the flow rate of the other of the streams; and monitoring the value of the control parameter in a stream leaving the mixing chamber. In one embodiment, the monitoring is continuous. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da navedeni postupak obuhvaća: miješanje toka hipokloritne otopine s tokom otopine amonijeve soli u komori za miješanje na početnom omjeru; držanje protoka jednog od navedenih tokova konstantnim i postepeno povećavanje ili smanjivanje protoka drugog od navedenih tokova; i nadziranje vrijednosti navedenog kontrolnog parametra u toku koji izlazi iz navedene komore za miješanje.
Use of a compound according to any one of claims 1-11 for the manufacture of a medicament for treatment of compromised lactation conditions, labour induction impairment, uterine atony conditions, excessive bleeding, inflammation, pain, abdominal pain, back pain, male and female sexual dysfunction, irritable bowel syndrome (IBS), constipation, gastrointestinal obstruction, autism, stress, anxiety, depression, anxiety disorder, surgical blood loss, post-partum haemorrhage, wound healing, infection, mastitis, placenta delivery impairment, osteoporosis, and for the diagnosis of cancer and placental insufficiency. 
Uporaba spoja prema bilo kojem od zahtjeva 1-3, naznačen time da se upotrebljava za pripremi lijeka za liječenje narušenih uvjeta dojenja, oštećenja nakon induciranog poroda, uvjeta atonije maternice, pretjeranog krvarenja, upale, boli, abdominalne boli, boli leđa, muške 1 žensko seksualne disfunkcije, sindroma iritabilnog crijeva (IBS), zatvora, gastrointenstinalnog začepljenja, autizma, stresa, anksioznosti, depresije, poremećaja anksioznosti, gubitka krvi uslijed kirurških zahvata, postporođajnog krvarenja, zacjeljivanja rana, infekcije, mastitisa, oštećenja porođajne posteljice i osteoporoze.
In a first variation of said third embodiment of a fabric according to the invention 210, the first inner breathable layer 211 is constituted by a diffusely macroperforated fabric. 
Tkanina u skladu s patentnim zahtjevima 1, 3, 41 8, naznačena time, da se navedeni prvi unutarnji prozračni sloj
Most preferably, the cellulose polymer is hydroxypropylmethyl cellulose. 
Najpovoljnije, celulozni polimer je hidroksipropilmetil celuloza.
The effect on histamine-simulated acid secretion of the Heidenhain pouch dog, administered with 0.25 umol/l of the compound of the invention was determined, the mean percentage inhibition after 1-3 hours (mean, n=2) is 91%. 
Učinak lučenja kiseline stimuliran s histaminom u psima s Heidenhain-ovom vrećicom, kojima je davano 0.25 Pmol/I spoja iz ovoga izuma, određen kao srednji postotak inhibicije nakon 1-3 h (srednje, n=2), je iznosio 91 %.
A transmission system, a receiver and a method for satellite signal transmission, wherein the satellite signals includes respective data streams consisting of a sequence of data packets. 
Metoda za prijenos satelitskog signala koja obuhvaća jednotipski MPEG-TS tok (3) podataka koji se sastoji od sekvence paketa podataka, pri čemu navedena metoda obuhvaća korake:
Preferably, the ampule member includes at least one opening therein that is sealed from fluid communication with the fluid chamber when the ampule member is in the first position, and is in fluid communication with the fluid chamber when the ampule member is in the second position. In a preferred embodiment, the filter assembly divides the upper chamber of the fluorescence analysis cartridge into a front chamber and a rear chamber. 
Sustav kazete za analizu prema zahtjevu 8, naznačen time, da je u kazeti za analizu daha komora za dah zabrtvljena prema fluidnoj komori kada je filterski sklop u prvoj poziciji, te time, da je u fluorescentnoj kazeti za analizu gornja komora zabrtvljena prema fluidnoj komori kada je filterski sklop u prvoj poziciji.
Pre-fusion RSV F polypeptide according to any of the claims 1-14, a nucleic acid molecule according to claim 15 and/or a vector according to claim 16 for use in inducing an immune response against RSV F protein. 
Prefuzijski RSV F polipeptid prema bilo kojem od zahtjeva 1-14, molekula nukleinske kiseline prema zahtjevu 15 iili vektor prema zahtjevu 16 naznačen time što je za upotrebu za induciranje imunološkog odgovora protiv proteina RSV F.
Method according to claims 11 - 12, characterized in that it is provided for a part of gaseous fuel in liquid state when operating in gaseous fuel mode to be discharged from the fuel rail (2) and discharging the part of gaseous fuel in liquid phase from the fuel rail (2) when operating in gaseous fuel mode is a connection of fuel rail (2) with the gaseous fuel tank (6). 
Metoda u skladu sa bilo kojim od zahtjeva 11-12, naznačena time da je predviđeno za dio plinovitog goriva u tekućem stanju tijekom rada u načinu rada plinovitog goriva da se ispušta iz razvodnika goriva (2) i ispuštanje dijela plimovitog goriva u tekućoj fazi iz razvodnika goriva (2) tijekom rada u načinu rada plinovitog goriva pomoću spoja razvodnika goriva (2) sa spremnikom (6) plinovitog goriva.
It has previously been found that the combination of a serotonin reuptake inhibitor with a compound having 5-HT2C antagonistic or inverse agonistic effect (compounds having a negative efficacy at the 5-HT2C receptor) provides a considerable increase in the level of 5-HT in terminal areas, as measured in microdialysis experiments (WO 01/41701). 
Već se ranije našlo da kombinacija inhibitora ponovne pohrane serotonina sa spojem koji ima učinak antagonista ili obrnutog agonista 5-HT2c (spojevi koji negativno djeluju na receptor 5-HT2c) omogućuje znatno povećanje na razini krajnjih područja 5-HT, što su pokazala mjerenja u mikrodijalitičkim pokusima (WO 01/41701).
Accordingly, the ability of a test compound to compete with the “radio-labeled compound of Formula (I)” for the binding to the RUP25 receptor directly correlates to its binding affinity. 
Prema tome, sposobnost test spoja da se natječe sa "radiološki označenim spojem Formule (I)" za vezivanje na RUP25 receptor u izravnoj je korelaciji s njegovim afinitetom vezivanja.
a screw positioned inside of the sieve to extract juice from a material; 
vijak (300) smješten unutar sita (200) za ekstrakciju soka iz materijala;
(viii) It has a sialylation pattern which is altered compared to the sialylation pattern of at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
(viii) ima primijenjeni uzorak sijaliliranja u usporedbi s uzorkom sijaliliranja za pripravak s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
or R12 and any one of R8, R9, R, R′, R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy; 
R12 i bilo koji od R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člam azaciklički prsten, pri čemu taj prsten može biti prema potrebi supstituiran sa sljedećima: halogen, cijano, hidroksil, C,-Cg alkil ili C,-Cg alkoksi; njeQili l;i
A highly concentrated, stable pharmaceutical anti-HER2 antibody formulation according to claim 1, wherein the anti-HER2 antibody concentration is 100 to 150 mg/ml, 120 ± 18 mg/ml, about 110 mg/ml, about 120 mg/ml, or about 130 mg/ml, respectively. 
Visoko koncentrirana, stabilna farmaceutska formulacija protutijela anti-HER2 prema zahtjevu 1 ili zahtjevu 2, naznačena time, da koncentracija protutijela anti-HER2 je od 100 do 150 mg/ml ili oko 120 +18 mg/ml ili oko 110 mg/ml ili oko 120 mg/ml ili oko 130 mg/ml.
represents a hydrogen or halogen atom, a linear or branched (C1-C6)alkyl group, or a linear or branched (C1-C6)alkoxy group, 
Rs predstavlja atom vodika ili halogena, ravnu ili razgrananu (C;-Cg) alkilnu skupinu, ili ravnu ili razgrananu (C;-Cg) alkoksi skupinu,
According to a further aspect means can be provided for evacuating the at least two thermoblocks associated with the brewing chambers by selectively providing a fluid connection between the thermoblocks with a thermoblock-evacuating outlet. 
Prema slijedećem aspektu može se ugraditi i mehanizam za pražnjenje najmanje dva termobloka povezana s komorama za kuhanje omogućavanjem selektivnog fluidnog kontakta između termoblokova s izlazom za pražnjenje termoblokova.
A composition for admixture with water, wherein the composition is optionally presented in two or more parts and comprises: 
Pripravak namijenjen miješanju s vodom, naznačen time što pripravak može biti prisutan u dva ili više dijelova i sadrži:
the displacement of the controllable lateral segments (2.2) with reference to the bottom of the box (2.1) is regulated by the position of levers (6.3); and 
da otvorenost upravljivih bočnih segmenta (2.2) u odnosu na dno sanduka (2.1) se regulira položajima poluga (6.3); i
The heavy chain of an antibody according to the disclosure may comprise a CDRH2 sequence of amino acids 50 to 68 (RIRTKSSNYATYYAASVKG) of SEQ ID NO: 4 or SEQ ID NO: 6, wherein one, two or three of these amino acids may be substituted by a different amino acid. 
Antitijelo ili njegov fragment u skladu sa patentnim zahtjevom 1, koje se natječe sa mAb 0170 za vezivanje za SEQ ID NO:1 koja predstavlja aminokiselinsku sekvencu humanog TREM-I, gdje mAb 0170 sadrži teški lanac koji sadrži sekvencu SEQ ID NO: 4, i laki lanac koji sadrži sekvencu SEQ ID NO: 5.
a second layer that consists of: 
A omotač se sastoji od:
polymerization means to polymerize said profile; characterized by said outer surface (15B) of said profile (15) having a sinusoidal shape with respect to an axial cross-sectional plane. 
sredstva za polimerizaciju da polimeriziraju spomenuti profil; naznačeno time da spomenuta vanjska površina (15B) spomenutog profila (15) ima sinusoidan oblik u odnosu na ravninu osnog poprečnog presjeka.
delivering separate flows of a first fluid and a second fluid through a drill string; 
dovođenje odvojenih tokova prvog fluida i drugog fluida (16, 18) kroz svrdla za bušenje (14);
In certain embodiments, the polypeptide may have the following arrangement from N-terminus to C-terminus: 10Fn3 domain-hinge-Fc domain. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-4, gdje polieptid ima slijedeći aranžman od N-terminusa do C-terminusa: zglob-Fc domen-linker-'*Fn3 domen.
The composition according to claim 1 wherein the GPR119 agonist has an EC50 of less than 10 µM. 
Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist ima EC50 manji od 10 uM.
treating the dicyclohexylamine salt of compound of formula I optionally in the presence of an organic solvent to form a salt with tert butyl amine 
tretiranje dicikloheksilamin soli spoja formule I opcijski u prisustvu organskog otapala da bi se dobila sol s terc-butil aminom.
The reaction mixture was then acidified with 6N hydrochloric acid (200 ml.), evaporated under vacuum to remove the t-butanol and extracted with ether (2 X 250 ml.l. 
Reakcijska smjesa se tada zakiseli sa 6N klorovodičnom kiselinom (200 ml.), ispari se u vakuumu da se ukloni t-butanol i ekstrahira se sa eterom (2 x250 ml.).
The system according to claim 1 wherein the spray nozzle is positioned along an internal conveyor of harvested forage. 
Sustav prema zahtjevu 1, naznačen time što je mlaznica za raspršivanje smještena duž internog transportera požnjevene krupne stočne hrane.
A fast dissolving orally dispersible tablet according to any proceeding claim, wherein it further comprises a diluent providing a pleasant sweet taste and cooling sensation such as mannitol, sorbitol and/or dextrate, a disintegrant such as crospovidone or sodium starch glycolate, one or more flavouring/sweetening agents such as menthol, lemon, sucralose and/or vanilla, a glidant such as talc or colloidal silicon dioxide and a lubricant such as magnesium stearate 
Brzo topljiva oralno raspadljiva tableta prema bilo kojem od prethodnih zahtjeva, naznačena time da dalje sadrži razrjeđivač koji pruža ugodan sladak okus i osjećaj hlađenja poput manitola, sorbitola i/ili dekstrata, sredstvo za raspadanje poput -krospovidona ili glikolata natrijevog škroba, jedno ili oviše sredstava za aromatizaciju/zaslađivanje poput mentola, limuna, sukraloze i/ili vanilije, sredstvo za klizanje poput talka ili koloidnog silicijevog dioksida i mazivo poput magnezijevog stearata.
Electronic device with an air cleaner according to claim 1, with a machine housing, wherein the air cleaner is provided at or on the inside of the machine enclosure. 
Elektronički uređaj s pročistačem zraka sukladno jednom od zahtjeva 9 do 15, osobito uređaj za zabavu, kockanje i/ili klađenje s kućištem stroja, pri čemu je pročistač zraka smješten na ili unutar kućišta stroja.
A recombinant host cell comprising the nucleic acid molecule according to claim 5 . A coating for a medical device comprising a polypeptide according to claim 1 . 
Rekombinantna stanica domaćin koja sadrži molekulu nukleinske kiseline sukladno patentnom zahtjevu 4 i/ili vektor sukladno patentnom zahtjevu 5.
This structure is defined by a concave front wall 6, a peripheral mantle 8 roughly in the shape of an upturned U, and a rear wall (not shown), which is partially open to receive the water reservoir 20 (only the upper end portion thereof being shown in the Figure). 
Ovu strukturu definira udubljena prednja stijenka 6, periferni plašt 8, uglavnom oblika prema gore okrenutog slova U, a stražnja je stijenka (nije prikazano) djelomično otvorena kako bi se moglo umetnuti spremnik s vodom 20 (na Slici je prikazan samo njegov gornji dio).
A process according to claim 9 wherein the resulting solution of step (a) is transferred to a separate reactor and contacted with the compound of formula (1) or a solution thereof. 
Postupak prema zahtjevu 8 naznačen time da se dobivena otopina iz koraka (a) prebacuje u odvojeni reaktor i dovodi u kontakt sa spojem s formulom (1) ili s njegovom otopinom.
wherein said emulsion-forming means comprise unattached stirring members (104) for increasing the emulsion of liquid components when the washing and separating container (1) is subjected to mechanical stirring, a force equal to the force imparted by manual action being sufficient to create said emulsion, and 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje je element (104) za miješanje pasivno sredstvo koje vrši svoje djelovanje nakon miješanja spremnika (1) i djeluje po inerciji.
Cu, Zn, Mg, Fe, B, Mo, Co, in the form of sulfides, oxides and carbonates. 
Cu, Zn, Mg, Fe, B, Mo, Co u obliku sulfida, oksida ili karbonata.
The dry powder formulation according to claim 7, wherein said high energy apparatus is a mechano-fusion apparatus. 
Formulacija suhog praška prema patentnom zahtjevu 5, naznačeno time da visokoenergijska aparatura jest mehano-fuzijska aparatura.
The use of a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: 
Uporaba tvari formule I [image] ili njene farmaceutski prihvatljive soli, pri čemu:
The DNA-targeting RNA provides target specificity to the complex by comprising a nucleotide sequence that is complementary to a sequence of a target DNA. 
(i) segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran ciljanom slijedu u ciljanoj DNA, i
The method of claim 7, wherein said opening is along a long side of the generally rectangular bag (20). 
Postupak iz patentnog zahtjeva 7, naznačen time, da se navedeni otvor nalazi na dužoj stranici pravokutne vrećice